Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ipilimumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor. It specifically targets cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein receptor on T cells that downregulates the immune response. By blocking CTLA-4, ipilimumab enhances the activation and proliferation of T-cells, thereby promoting an anti-tumor immune response. Ipilimumab is primarily used in the treatment of various cancers including unresectable or metastatic melanoma, renal cell carcinoma (RCC), colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, and esophageal squamous cell carcinoma. It can be administered alone or in combination with other agents such as nivolumab[1][2][3][5][6][7].
- Brand names
- Yervoy
- Other names
- ipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab.